Radiolabeling DOTA-peptides with 90 Y and 177 Lu to a high specific activity

Radionuclide Peptide Cancer Therapy

Volumn , Issue , 2016, Pages 119-125

  Breeman, Wouter A P ^a   de Blois, Erik ^a   Bakker, Willem H ^a   Krenning, Eric P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85122646876     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (19)

1. Otte A, Jermann E, Behe M, et al. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med 1997; 24:792-795.
2. Erion JL, Bugaj JE, Schmidt MA, Wilhelm RR, Srinivasan A. High radiotherapeutic efficacy of [Lu-177]-DOTA-Y3-octreotate in a rat tumor model. J Nucl Med 1999; 40:223.
3. Krenning EP, Valkema R, Kooij PP, et al. The role of radioactive somatostatin and its analogues in the control of tumor growth. Recent Results Cancer Res 2000; 153:1-13.
4. Breeman WA, de Jong M, Kwekkeboom DJ, et al. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med 2001; 28:1421-1429.
5. Kwekkeboom D, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J Nucl Med 2000; 41:1704-1713.
6. Kwekkeboom DJ, Bakker WH, van der Pluijm ME, et al. Lu-177-DOTA-Tyr3-Octreotate: comparison with In-111-DTPA-octreotide in patients. Eur J Nucl Med 2000; 27:273.
7. Bernhardt P, Kolby L, Johanson V, Nilsson O, Ahlman H, Forssell-Aronsson E. Biodistribution of 111in-DTPA-D-Phe1-octreotide in tumor-bearing nude mice: influence of amount injected and route of administration. Nucl Med Biol 2003; 30:253-260.
8. Basso N, Lezoche E, Speranza V. Studies with bombesin in man. World J Surg 1979; 3:579-585.
9. van Hagen PM, Breeman WA, Reubi JC, et al. Visualization of the thymus by substance P receptor scintigraphy in man. Eur J Nucl Med 1996; 23:1508-1513.
10. Bunemann M, Hosey MM. G-protein coupled receptor kinases as modulators of G-protein signalling. J Physiol 1999; 517:5-23.
11. Szilagyi ETE, Kovacs Z, Platzek J, Raduchel B, Brücher E. Equilibria and formation kinetics of some cyclen derivative complexes of lanthanides. Inorganica Chemica Acta 2000; 298:226-234.
12. Moerlein SM, Welch MJ. The chemistry of gallium and indium as related to radiopharmaceutical production. Int J Nucl Med Biol 1981; 8:277-287.
13. Breeman WA, De Jong M, Visser TJ, Erion JL, Krenning EP. Optimizing conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. Eur J Nucl Med Mol Imaging 2003; 30:917-920.
14. Kukis DL, DeNardo SJ, DeNardo GL, O'Donnell RT, Meares CF. Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates. J Nucl Med 1998; 39:2105-2110.
15. Liu S, Edwards DS. Stabilization of (90)y-labeled DOTA-biomolecule conjugates using gentisic acid and ascorbic acid. Bioconjug Chem 2001; 12:554-558.
16. Liu S, Ellars CE, Edwards DS. Ascorbic acid: useful as a buffer agent and radiolytic stabilizer for metalloradiopharmaceuticals. Bioconjug Chem 2003; 14:1052-1056.
17. Lebedev NA, Novgorodov AF, Misiak R, Brockmann J, Rosch F. Radiochemical separation of no-carrier-added 177Lu as produced via the 176Yb(n,gamma)177Yb-> 177Lu process. Appl Radiat Isot 2000; 53:421-425.
18. Breeman WA, van der Wansem K, Bernard BF, et al. The addition of DTPA to [177Lu-DOTA0, Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity. Eur J Nucl Med Mol Imaging 2003; 30:312-315.
19. Breeman WA, De Jong MT, De Blois E, Bernard BF, De Jong M, Krenning EP. Reduction of skeletal accumulation of radioactivity by co-injection of DTPA in [90Y-DOTA0, Tyr3]octreotide solutions containing free 90Y3 +. Nucl Med Biol 2004; 31:821-824.